Elevation Point Wealth Partners LLC Sells 1,616 Shares of Natera, Inc. (NASDAQ:NTRA)

Elevation Point Wealth Partners LLC reduced its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 24.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,020 shares of the medical research company's stock after selling 1,616 shares during the quarter. Elevation Point Wealth Partners LLC's holdings in Natera were worth $710,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. LRI Investments LLC bought a new stake in shares of Natera in the 4th quarter worth approximately $29,000. Blue Trust Inc. boosted its position in shares of Natera by 223.7% in the 4th quarter. Blue Trust Inc. now owns 301 shares of the medical research company's stock worth $48,000 after purchasing an additional 208 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares in the last quarter. Principal Securities Inc. boosted its position in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after purchasing an additional 332 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 9,563 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $1,323,614.83. Following the completion of the sale, the chief executive officer now directly owns 212,541 shares in the company, valued at $29,417,799.81. This represents a 4.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Michael Burkes Brophy sold 2,562 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $354,606.42. Following the completion of the sale, the chief financial officer now owns 75,557 shares of the company's stock, valued at $10,457,844.37. This trade represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 59,755 shares of company stock worth $8,898,589 in the last three months. Corporate insiders own 7.60% of the company's stock.

Natera Price Performance

NASDAQ NTRA opened at $165.34 on Monday. The business's fifty day moving average price is $154.56 and its 200-day moving average price is $158.46. The stock has a market capitalization of $22.58 billion, a price-to-earnings ratio of -93.94 and a beta of 1.74. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company's revenue was up 36.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.56) EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Robert W. Baird boosted their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Royal Bank of Canada started coverage on Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price objective on the stock. Barclays upped their price objective on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Morgan Stanley upped their price objective on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, UBS Group upped their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Natera currently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.